Category: 883944-52-3

ACE2:S1 RBD interaction-targeted peptides and small molecules as potential COVID-19 therapeutics was written by Chitsike, Lennox;Krstenansky, John;Duerksen-Hughes, Penelope J.. And the article was included in Advances in Pharmacological and Pharmaceutical Sciences in 2021.Reference of 883944-52-3 This article mentions the following:

The COVID-19 pandemic that began in late 2019 continues with new challenges arising due to antigenic drift as well as individuals who cannot or choose not to take the vaccine. There is therefore an urgent need for addnl. therapies that complement vaccines and approved therapies such as antibodies in the fight to end or slow down the pandemic. SARS-CoV-2 initiates invasion of the human target cell through direct contact between the receptor-binding domain of its Spike protein and its cellular receptor, angiotensin-converting enzyme-2 (ACE2). The ACE2 and S1 RBD interaction, therefore, represents an attractive therapeutic intervention to prevent viral entry and spread. In this study, we developed a proximity-based AlphaScreen assay that can be utilized to quickly and efficiently screen for inhibitors that perturb the ACE2:S1 RBD interaction. We then designed several peptides candidates from motifs in ACE2 and S1 RBD that play critical roles in the interaction, with and without modifications to the native sequences. We also assessed the possibility of reprofiling of candidate small mols. that previously have been shown to interfere with the viral entry of SARS-CoV. Using our optimized AlphaScreen assay, we evaluated the activity and specificity of these peptides and small mols. in inhibiting the binding of ACE2:S1 RBD. This screen identified cepharanthine as a promising candidate for development as a SARS-CoV-2 entry inhibitor. In the experiment, the researchers used many compounds, for example, N-(4-(4-Methylpiperazin-1-yl)benzyl)isoxazole-5-carboxamide (cas: 883944-52-3Reference of 883944-52-3).

N-(4-(4-Methylpiperazin-1-yl)benzyl)isoxazole-5-carboxamide (cas: 883944-52-3) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Isoxazole can be synthesised via a variety of methods. Examples include via the reaction of hydroxylamine with 1,3-diketones or derivatives of propiolic acid.Reference of 883944-52-3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies was written by Zhang, Shuangzhe;Gao, Chunhui;Das, Tuhin;Luo, Shuhong;Tang, Hao;Yao, Xinyi;Cho, Chih Yun;Lv, Jingqiao;Maravillas, Kino;Jones, Valerie;Chen, Xiaofeng;Huang, Ruopan. And the article was included in Journal of Immunological Methods in 2022.HPLC of Formula: 883944-52-3 This article mentions the following:

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has become a worldwide pandemic, and there is a pressing need for the rapid development of novel therapeutic strategies. SARS-CoV-2 viral entry is mediated by interaction between the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein and host cellular receptor, human angiotensin converting enzyme 2 (ACE2). The lack of a high throughput screening (HTS) platform for candidate drug screening means that no targeted COVID-19 treatments have been developed to date. To overcome this limitation, we developed a novel, rapid, simple, and HTS binding assay platform to screen potential inhibitors of the RBD-ACE2 complex. Three “neutralizing” mouse monoclonal antibodies capable of blocking the RBD-ACE2 interaction were identified using our binding assay and pseudovirus neutralization assay followed by further validation with the Focus Reduction Neutralization Test (FRNT), which analyzes the neutralization capacity of samples in the presence of live SARS-CoV-2. Furthermore, the consistency of our binding assay and FRNT results (R² = 0.68) was demonstrated by patients′ serum, of which were COVID-19 pos. (n = 34) and COVID-19 neg. (n = 76). Several small mols. selected for their potential to inhibit the Spike-ACE2 complex in silico were also confirmed with the binding assay. In addition, we have evaluated vaccine efficacy using binding assay platform and validated through pseudovirus neutralization assay. The correlation between binding assay & psuedovirus assay of the post vaccinated serum showed well correlated (R² = 0.09). Moreover, our binding assay platform successfully validated different Spike RBD mutants. These results indicate that our binding assay can be used as a platform for in vitro screening of small mols. and monoclonal antibodies, and high-throughput assessment of antibody levels after vaccination. When conducting drug screening, computer virtual screening lacks actual basis, construction of pseudoviruses is relatively complicated, and even FRNT requires a P3 laboratory There are few methods to determine the competitiveness of the target drug and SRBD or ACE2. Our binding assay can fill this gap and accelerate the process and efficiency of COVID-19 drug screening. In the experiment, the researchers used many compounds, for example, N-(4-(4-Methylpiperazin-1-yl)benzyl)isoxazole-5-carboxamide (cas: 883944-52-3HPLC of Formula: 883944-52-3).

N-(4-(4-Methylpiperazin-1-yl)benzyl)isoxazole-5-carboxamide (cas: 883944-52-3) belongs to isoxazole derivatives. Isoxazoles also form the basis for a number of drugs, including the COX-2 inhibitor valdecoxib (Bextra) and a neurotransmitter agonist AMPA. Isoxazoles are potent isosteres of pyridine and have been found to inhibit voltage-gated sodium channels for pain control, for the construction of tetracycline antibiotic derivatives, and as a therapeutic agent for depression.HPLC of Formula: 883944-52-3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem